Liu Xiong, Shu Shi, Kovács Mihály, Korn Edward D
Laboratory of Cell Biology, NHLBI, National Institutes of Health, Bethesda, Maryland 20892, USA.
J Biol Chem. 2005 Jul 22;280(29):26974-83. doi: 10.1074/jbc.M504453200. Epub 2005 May 16.
The cardiomyopathy (CM)-loop of the heavy chain of class-II myosins begins with a highly conserved Arg residue (whose mutation in human beta-cardiac myosin II results in familial hypertrophic cardiomyopathy). The CM-loop of Dictyostelium myosin II (Arg397-Gln407) is essential for its biological functions and biochemical activities. We found that the CM-loop of smooth muscle myosin II substituted partially, and the CM-loop of beta-cardiac myosin II less well, for growth, capping of surface receptors and development, and the actin-activated MgATPase and in vitro motility activities of purified myosins. There was little correlation between the biochemical and biological activities of the two chimeras and 19 point mutants, but only the five mutants with k cat/K actin values equivalent to wild-type myosin supported essentially full biological function. The three point mutations of Arg397 equivalent to those that result in hypertrophic cardiomyopathy in humans had minimal biological effects and different biochemical effects. The A400V mutation rendered full-length wild-type myosin almost completely inactive, both in vitro and in vivo, and the reverse V400A mutation in the cardiac CM-loop chimera restored almost full activity, even though the sequence still differed from wild-type in 7 of 11 positions. Transient kinetic studies of acto-subfragment-1 (S1) showed that the chimeras and the Ala/Val, Val/Ala mutations do not affect the equilibrium or the association and dissociation rate constants for either ATP or ADP binding to acto-S1 or the rate of ATP-induced dissociation of acto-S1. We conclude that the Ala/Val, Val/Ala mutations affect the release of Pi from acto-S1.ADP.Pi. In addition, Val at position 400 substantially reduces the affinity of actin for S1 in the absence of nucleotide.
II类肌球蛋白重链的心肌病(CM)环始于一个高度保守的精氨酸残基(其在人β-心脏肌球蛋白II中的突变导致家族性肥厚型心肌病)。盘基网柄菌肌球蛋白II的CM环(精氨酸397 - 谷氨酰胺407)对其生物学功能和生化活性至关重要。我们发现,平滑肌肌球蛋白II的CM环部分替代,β-心脏肌球蛋白II的CM环替代效果稍差,对生长、表面受体封端和发育以及纯化肌球蛋白的肌动蛋白激活的MgATP酶和体外运动活性有影响。两种嵌合体和19个点突变体的生化活性与生物学活性之间几乎没有相关性,但只有五个kcat/K肌动蛋白值与野生型肌球蛋白相当的突变体支持基本完全的生物学功能。与导致人类肥厚型心肌病的突变等效的精氨酸397的三个点突变具有最小的生物学效应和不同的生化效应。A400V突变使全长野生型肌球蛋白在体外和体内几乎完全失活,而心脏CM环嵌合体中的反向V400A突变恢复了几乎完全的活性,尽管该序列在11个位置中的7个位置仍与野生型不同。对肌动蛋白-亚片段1(S1)的瞬态动力学研究表明,嵌合体以及丙氨酸/缬氨酸、缬氨酸/丙氨酸突变不影响ATP或ADP与肌动蛋白-S1结合的平衡、缔合和解离速率常数,也不影响ATP诱导的肌动蛋白-S1解离速率。我们得出结论,丙氨酸/缬氨酸、缬氨酸/丙氨酸突变影响磷酸根从肌动蛋白-S1.ADP.Pi的释放。此外,400位的缬氨酸在没有核苷酸的情况下大幅降低了肌动蛋白对S1的亲和力。